Optimizing Higher Throughput Methods to Assess Drug–Drug Interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 In Vitro Using a Single Point IC50

This publication has 27 references indexed in Scilit:

• Fully automated analysis of activities catalysed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential
  Xenobiotica, 1999
• High-throughput approaches for evaluating absorption, distribution, metabolism and excretion properties of lead compounds
  Current Opinion in Chemical Biology, 1998
• Inhibition and Induction of Cytochrome P450 and the Clinical Implications
  Clinical Pharmacokinetics, 1998
• Human cytochrome P450s: selectivity and measurement in vivo
  Xenobiotica, 1998
• HPLC-API/MS/MS: a powerful tool for integrating drug metabolism into the drug discovery process
  Drug Discovery Today, 1997
• Microtiter Plate Assays for Inhibition of Human, Drug-Metabolizing Cytochromes P450
  Analytical Biochemistry, 1997
• Preclinical Drug Metabolism in the Age of High-Throughput Screening: An Industrial Perspective
  Pharmaceutical Research, 1997
• Chapter 30. Inhibition of Cytochrome P-450 and Implications in Drug Development
  Published by Elsevier ,1997
• Goals, Design, Timing, and Future Opportunities for Nonclinical Drug Metabolism Studies
  Toxicologic Pathology, 1995
• A Microassay for Measuring Cytochrome P450IA1 and Cytochrome P450IIB1 Activities in Intact Human and Rat Hepatocytes Cultured on 96-Well Plates
  Analytical Biochemistry, 1993